ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PCVX / earnings
KRYS (73) RGEN (61) TWST (47) QGEN (72) ⌘ Pro Terminal →

Vaxcyte Inc. (PCVX) Next Earnings Date & Expected ±10.3% Move

$60.62 -2.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $60.26

Vaxcyte Inc. (PCVX) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $9.76B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PCVX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PCVX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Vaxcyte Inc. (NASDAQ: PCVX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $60.62 (-2.27% 1D, market cap $9.76B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, PCVX ranks #269 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PCVX compare to KRYS and RGEN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PCVX carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -27.6%. By comparison, KRYS (Krystal Biotech Inc.) holds a B grade (73/100 RQD, P/E 46.9x, ROIC 16.5%, cap $9.84B) and RGEN (Repligen Corporation) posts a C- grade (61/100 RQD, P/E N/A, ROIC 2.3%, cap $10.03B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PCVX?
▼

Per PCVX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001649094), Vaxcyte Inc. generated $2.59B in revenue (+62.2% YoY), -$766.6K in net income, and -$669.3M in free cash flow against $3.00B in total assets and $142.7M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $60.26 (-0.60%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510049
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Cash (5)Whales (12)SEC (16)Macro (10)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-4.1% Base Target
$95 Bull$58 Base$45 Bear
📬 FREE PCVX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PCVX)Realized 20D OHLCV Swing Band: ±10.3%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY PCVX SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (33% of score)

Altman Z-Score 18.11 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (24% of score)

20D Institutional Volume Accumulation (±10.3% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality5/20 pts (-15 pt drag)

Capital intensity & 0% operating margin leave 15 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
57
Grade C$67.55-6.4% Next Q
Q2 (-2Q)
54
Grade C-$63.23-2.8% Next Q
Q3 (-1Q)
52
Grade C-$61.46-1.4% Next Q
Current
49
Grade D$60.62-5.4% Hist 90D α
Trajectory: C (57) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PCVX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PCVX currently carries a cautious 49/100 (D) rating due to Cash Engine Quality (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($61.64) and Max Pain ($63.65) forces dealer call-delta covering toward $95.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PCVX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PCVX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 49%NO 51%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±10.3% Swing Band

±$6.24 Expected Swing
$54.38 (-10.3%)Spot $60.62$66.86 (+10.3%)
MODEL EARNINGS SETUP GAUGE

PCVX Quantitative Pre-Earnings Setup: 49/100

Trailing EPS: $0.00 • YoY Revenue Growth: 19.8%

Model Bullish Setup (49/100)Model Risk Weight (51/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$2.59B-$766.6K-$669.3M52%
FY 20242024-12-31$1.59B-$463.9K-$475.1M52%
FY 20232023-12-31$1.31B-$402.3K-$296.8M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PCVX)

  • ✓Walkthrough of PCVX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PCVX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.64%🛡️ HOLDING TREND SUPPORT
2026-11-03O $62.61H $62.61L $60.62C $60.62VOL 1.71M
RES: $100.9SUP: $56.97SMA50: $61.64SMA200: $57.27
$93.93$80.75$67.57$54.39$41.21RES $100.9SUP $56.97$60.622026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PCVX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PCVX Butterfly Map → + Track PCVX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
16.8%/yr Implied 5Y Growth

vs. +62.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PCVX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PCVX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PCVX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PCVX)

Health Care Rank #269 of 1015 ⚔️ KRYS vs PCVX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PCVX vs. KRYS, RGEN, TWST, QGEN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Vaxcyte Inc. (PCVX) ranks #269 by composite RQD confidence (49/100, grade D) and #113 by equity capitalization ($9.76B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while KRYS leads on capital efficiency and profitability with 16.5% ROIC and — gross margin. KRYS currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with PCVX at 49/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PCVX ACTIVE
Vaxcyte Inc.
D 49/100 — — -27.6% -2.27% $9.76B Benchmark Subject
KRYS
Krystal Biotech Inc.
B 73/100 46.9x — 16.5% -10.95% $9.84B /krys-vs-pcvx →
RGEN
Repligen Corporation
C- 61/100 — 88.2% 2.3% -2.25% $10.03B /rgen-vs-pcvx →
TWST
Twist Bioscience Corporation
D 47/100 — 94.2% -11.7% -15.54% $10.13B /twst-vs-pcvx →
QGEN
Qiagen N.V.
B 72/100 24.4x 62.2% 8.0% +0.26% $10.35B /qgen-vs-pcvx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001649094 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vaxcyte Inc. (PCVX) reported GAAP revenue of $2.59B (+62.2% vs. FY2024 revenue of $1.59B , and +97.3% cumulative change since FY2023) , GAAP net income of -$766.6K, operating cash flow of -$655.6M, and free cash flow of -$669.3M (-40.9% YoY). On the balance sheet, PCVX closed FY2025 with $3.00B in total assets against $142.7M in total debt (Altman Z-Score: 18.11, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.59B -$766.6K -$655.6M -$669.3M $3.00B $142.7M
FY2024 (FY) 2024-12-31 $1.59B -$463.9K -$452.6M -$475.1M $3.51B $92.5M
FY2023 (FY) 2023-12-31 $1.31B -$402.3K -$296.8M -$296.8M $5.42B $1.27B

3. PCVX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PCVX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Vaxcyte Inc. (NASDAQ: PCVX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $60.62 (-2.27% 1D, market cap $9.76B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, PCVX ranks #269 in composite RQD confidence.

How does PCVX compare to KRYS and RGEN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PCVX carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -27.6%. By comparison, KRYS (Krystal Biotech Inc.) holds a B grade (73/100 RQD, P/E 46.9x, ROIC 16.5%, cap $9.84B) and RGEN (Repligen Corporation) posts a C- grade (61/100 RQD, P/E N/A, ROIC 2.3%, cap $10.03B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PCVX?

Per PCVX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001649094), Vaxcyte Inc. generated $2.59B in revenue (+62.2% YoY), -$766.6K in net income, and -$669.3M in free cash flow against $3.00B in total assets and $142.7M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PCVX trading relative to its 50-day, 200-day, and 52-week technical levels?

PCVX last traded at $60.62 (-2.27% on volume of 1,320,546 shares), positioning the stock -1.65% below its 50-day simple moving average ($61.64) and +5.85% above its 200-day simple moving average ($57.27). Across its 52-week range of $39.87 to $90.75, PCVX sits at the 40.8% percentile with a 14-day RSI of 48.7 (NEUTRAL RANGE) and an implied next-earnings move of ±10.3% ($54.38 to $66.86).

Direct Sub-Reports: PCVX RQD Cockpit PCVX 12M Forecast PCVX Earnings & Move PCVX Dividends & DRIP PCVX Insiders & 13F PCVX Whale Options PCVX Profit Sankey PCVX News & Why
ROARABLE RATING BRIEF • RQD 49/100 (D) ✓ SEC XBRL & RQD VERIFIED

PCVX — Vaxcyte Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Vaxcyte Inc. (PCVX) earns a live Roarable RQD composite score of 49/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $60.62 (-2.27% 1D, market capitalization $9.76B).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -27.6%, gross margin of —, operating margin of -33.5%, and free cash flow yield of -6.79%.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (16/20): Incorporates a 1.07x equity beta, Altman Z-Score of 18.11, Piotroski F-Score of 4/9, and Debt/Equity of 0.05x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Vaxcyte Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile lists a market capitalization of $9.9B. — describes its specific products, customers, or revenue model. Reported revenue in the financial periods is — for each year provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Vaxcyte Inc. (PCVX) reported $2.59B in annual revenue (up from $1.59B in FY2024, +62.2% YoY) and -$766.6K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.31B revenue, -$402.3K net income) through FY2025, PCVX scaled operating cash flow to -$655.6M and free cash flow to -$669.3M, backed by $3.00B in total assets against $142.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 49/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of -6.79% and institutional whale pillar of 12/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $39.87 – $90.75 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -33.5% operating margins and a 1.07x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), PCVX carries a macro regime beta of 1.07 and gross margin of —.

  • Key Question #1: Can PCVX sustain or expand its -33.5% operating margin and -27.6% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.59B and free cash flow of -$669.3M, how will capital allocation balance growth reinvestment against $142.7M in total debt?
  • Key Question #3: How sensitive is PCVX's 23.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.07x)?

PCVX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Vaxcyte Inc. (PCVX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PCVX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PCVX Bull vs. Bear Conversation Board — What's Your Call at $60.62?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PCVX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PCVX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $73.82 (+19.0%)
📌 Pinned Debate

The forensic balance sheet scores 16 of 20 with an Altman Z of 18.11 and Debt/Equity of 0.05, and the vaccine trial win drew a Guggenhe

Don't sleep on PCVX's setup in Health Care. The forensic balance sheet scores 16 of 20 with an Altman Z of 18.11 and Debt/Equity of 0.05, and the vaccine trial win drew a Guggenheim price target raise.. Beta of 1.07 means it moves fast when momentum turns, and the 5-pillar RQD gauge (49/100) backs up the fundamental quality.

CapAlloc_Nerd 🐂 BULL

@SiliconVal_Bull Agree on the RQD 49/100 quality, though with 1.07 beta I'm scaling in with half-size at $62.03 and keeping dry powder in case we test $57.69.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $46.52 (-25.0%)
Spot @ $62.03

ROIC of -27.6%, FCF of -$669.3M in FY 2025, and a $1.15 Billion financing signal an unfunded cash engine and dilution pressure.

I respect the product at Vaxcyte Inc., but the stock at $62.03 is a different story. ROIC of -27.6%, FCF of -$669.3M in FY 2025, and a $1.15 Billion financing signal an unfunded cash engine and dilution pressure.. FCF yield is -6.79% and RQD sits at 49/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%